Therapeutic Duplication as a Medication Error Risk in Fixed-Dose Combination Drugs for Dyslipidemia: A Nationwide Study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background & Objectives: Fixed-dose combinations (FDCs) offer advantages in adherence and cost-effectiveness compared to free combinations (FCs), but they can also complicate the prescribing process, potentially leading to therapeutic duplication (TD). This study aimed to identify the prescribing patterns of FDCs for dyslipidemia and investigate their associated risk of TD. Methods: This was a retrospective cohort study involving drugs that included statins, using Health Insurance Review & Assessment Service- National Patient Sample (HIRA-NPS) data from 2018. The unit of analysis was a prescription claim. The primary outcome was TD. The risk ratio of TD was calculated and adjusted for patient, prescriber, and the number of cardiovascular drugs prescribed using a multivariable Poisson model. Results: Our study included 252,797 FDC prescriptions and 515,666 FC prescriptions. Of the FDC group, 46.52% were male patients and 56.21% were aged 41 to 65. Ezetimibe was included in 71.61% of the FDC group, but only 0.25% of the FC group. TD occurred in 0.18% of the FDC group, and the adjusted risk ratio of TD in FDC prescriptions compared to FC was 6 . 44 (95% CI 5 . 30-7. 82). Conclusions: Prescribing FDCs for dyslipidemia was associated with a higher risk of TD compared to free combinations. Despite the relatively low absolute prevalence of TD, the findings underline the necessity for strategies to mitigate this risk when prescribing FDCs for dyslipidemia. Our study suggests the potential utility of Clinical Decision Support Systems and standardizing nomenclature in reducing medication errors, providing valuable insights for clinical practice and future research.
Abstract
Background & Objectives: Fixed-dose combinations (FDCs) offer advantages in adherence and cost-effectiveness compared to free combinations (FCs), but they can also complicate the prescribing process, potentially leading to therapeutic duplication (TD). This study aimed to identify the prescribing patterns of FDCs for dyslipidemia and investigate their associated risk of TD. Methods: This was a retrospective cohort study involving drugs that included statins, using Health Insurance Review & Assessment Service- National Patient Sample (HIRA-NPS) data from 2018. The unit of analysis was a prescription claim. The primary outcome was TD. The risk ratio of TD was calculated and adjusted for patient, prescriber, and the number of cardiovascular drugs prescribed using a multivariable Poisson model. Results: Our study included 252,797 FDC prescriptions and 515,666 FC prescriptions. Of the FDC group, 46.52% were male patients and 56.21% were aged 41 to 65. Ezetimibe was included in 71.61% of the FDC group, but only 0.25% of the FC group. TD occurred in 0.18% of the FDC group, and the adjusted risk ratio of TD in FDC prescriptions compared to FC was 6 . 44 (95% CI 5 . 30-7. 82). Conclusions: Prescribing FDCs for dyslipidemia was associated with a higher risk of TD compared to free combinations. Despite the relatively low absolute prevalence of TD, the findings underline the necessity for strategies to mitigate this risk when prescribing FDCs for dyslipidemia. Our study suggests the potential utility of Clinical Decision Support Systems and standardizing nomenclature in reducing medication errors, providing valuable insights for clinical practice and future research.
참고문헌 (44)
- Committee of Clinical Practice Guideline, "Korean guidelines for the management of dyslipidemia", The Korean Society of Lipid and Atherosclerosis, ~ (2022)
- Arnett DK, "2019 ACC", AHA guideline on the primary prevention of cardiovascular disease : A report of the american college of cardiology, Circulation, pp.2019, 140(11)[DOI]
- 조소미, "Dyslipidemia Fact Sheets in Korea 2020: an Analysis of Nationwide Population-based Data", 지질·동맥경화학회지, 10(2), pp.202~209 (2021), 한국지질동맥경화학회[DOI]
- Mach F, "2019 ESC", EAS guidelines for the management of dyslipidaemias : Lipid modification to reduce cardiovascular risk : The task force for the management of dyslipidaemias of the european society of cardiology(ESC)and european atherosclerosis society(EAS), 2019, pp.41(1), 111~188
- World report on ageing and health, , World Health Organization, ~ (2015)
- 김태응, "Measuring Trends in the Socioeconomic Burden of Disease in Korea, 2007-2015", 예방의학회지, 55(1), pp.19~27 (2022), 대한예방의학회[DOI]
- "Primary medical chronic disease management pilot project guide (translated title)", Ministry of Health and Welfare, ~ (2021)
- "Adherence to long-term therapies: Evidence for action", World Health Organization, ~ (2003)
- Bangalore S, "Fixed-dose combinations improve medication compliance : A meta-analysis", Am J Med, 120(8), pp.713~719 (2007)
- Chung S, "Effect of fixed-dose combination of ARB and statin on adherence and risk factor control : The randomized FIXAR study", Cardiol J, 29(5), pp.815~823 (2022)
- Castellano JM, "A polypill strategy to improve adherence : Results from the focus project", J Am Coll Cardiol, 64(20), pp.2071~2082 (2014)
- Roebuck MC, "Medication adherence leads to lower health care use and costs despite increased drug spending", Health Affairs, 30(1), pp.91~99 (2011)
- Poulter NR, "Medication adherence in hypertension", Journal of Hypertension, 38(4), pp.579~587 (2020)
- Moriarty F, "Fixed-dose combination antihypertensives and risk of medication errors", Heart, 105(3), pp.204~209 (2019)
- 양소영, "올바른 약물 이용 지원 시범사업 성과 연구", 보건사회연구, 40(3), pp.563~591 (2020), 한국보건사회연구원[DOI]
- 구현지, "고혈압 복합제 복용환자에서 동일계열약물 중복 현황", 한국임상약학회지, 32(2), pp.125~132 (2022), 한국임상약학회[DOI]
- "National health insurance reimbursement medicine list", Ministy of Health and Welfare, ~ (2018)
- Kim L, "A guide for the utilization of health insurance review and assessment service national patient samples", Epidemiol Health, 36, pp.e2014008~ (2014)
- "Drug utilization review" (2013)[URL]
- Jung SY, "Effect of a nationwide real-time drug utilization review system on duplicated nonsteroidal antiinflammatory drug prescriptions in Korea", Arthritis Care Res(Hoboken), 72(10), pp.1374~1382 (2020)
- "Therapeutic duplicate medication product list December 1, 2018", Health Insurance and Assessment Service, ~ (2018)
- "Notice on DUR review of therapeutic duplication for combination medicines and information on discontinued production, import, and supply of medicines", Health Insurance Review & Assessment Service, ~ (2020)
- Velo GP, "Medication errors : Prescribing faults and prescription errors", Br J Clin Pharmacol, 67(6), pp.624~628 (2009)
- Institute of Medicine (US) Committee on Quality of Health Care in America, "To err is human: Building a safer health system" (2000), National Academies Press(US)
- Tully MP, "The causes of and factors associated with prescribing errors in hospital inpatients", Drug Saf, 32(10), pp.819~836 (2009)
- Lambert BL, "Effect of orthographic and phonological similarity on false recognition of drug names", Soc Sci Med, 52(12), pp.1843~1857 (2001)
- Lambert BL, "Designing safe drug names", Drug Saf, 28(6), pp.495~512 (2005)
- Aronson JK, "Medication errors resulting from the confusion of drug names", Expert Opin Drug Saf, 3(3), pp.167~172 (2004)
- Bramley DE, "The ability of anaesthetists to identify generic medications from trade names", Anaesth Intensive Care, 37(4), pp.624~629 (2009)
- Kim S-J., "Patient safety incident reporting status and pharmacist intervention cases", Korean Pharmaceutical Association Patient Safety and Medication Administration Web Symposium (2022)
- Lee JH, "Proposals for nomenclature of generic drugs to prevent medication errors", J Kor Soc Health-Syst Pharm, 25(2), pp.159~168 (2008)
- 김정은, "상품명 처방전과 의약품 사용과오(Medication Error)의 상관성에 대한 기초연구", 약 학 회 지, 63(4), pp.238~246 (2019), 대한약학회[DOI]
- Gupta AK, "Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents:A meta-analysis", Hypertension, 55(2), pp.399~407 (2010)
- Pappa E, "Emerging fixed-dose combination treatments for hyperlipidemia", J Cardiovasc Pharmacol Ther, 24(4), pp.315~322 (2019)
- Sherrill B, "Single-pill vs free-equivalent combination therapies for hypertension : A metaanalysis of health care costs and adherence", J Clin Hypertens(Greenwich), 13(12), pp.898~909 (2011)
- Lee Y, "Consumption of single products versus fixed-dose combination medicines for hypertension and hyperlipidemia during 2015-2019 in South Korea", PLOS ONE, 16(12), pp.e0259467~ (2021)
- "Label: Zetia-ezetimibe tablet"[URL]
- Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
- "Best practices in developing proprietary names for human prescription drug products; guidance for industry", U. S. Food and Drug Administration, ~ (2020)
- "Are national efforts to reduce drug name confusion paying off? ISMP Medication Safety Alert", 1~6 (2018)
- Lee SJ, "Drug product name assignment casebook", Ministry of Food and Drug Safety, ~ (2022)
- "INN and Classification of Medical Products. Guidance on the use of international nonproprietary names (INNs) for pharmaceutical substances" (2017)[URL]
- Garcia BH, "Safety and efficiency of a new generic package labelling : A before and after study in a simulated setting", BMJ Qual Saf, 26(10), pp.817~823 (2017)
- Kuperman GJ, "Medication-related clinical decision support in computerized provider order entry systems : A review", J Am Med Inform Assoc, 14(1), pp.29~40 (2007)